Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

MeiraGTx (MGTX) stock in plain English

Free brief · no signupStart here
MGTXPublished Nov 15, 2026
MeiraGTx Holdings plc
Healthcare · Biotechnology
Develops genetic therapies for neurodegenerative disorders, ocular diseases, and salivary gland damage.
Assets:
Manufacturing hubsShannon and London plants supply viral vectors
Gene switch platformProprietary riboswitches regulate therapeutic protein output
Clinical pipelineActive programs address Parkinson's disease and xerostomia
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

83
OPS ScoreOperating finances
Latest quote
-2.16%$8.14
$795.53M
10.2×
$401.78M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 15, 2026Quotes updated Nov 20, 04:10 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was MGTX. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does MeiraGTx (MGTX) do?

MeiraGTx Holdings plc (MGTX) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Develops genetic therapies for neurodegenerative disorders, ocular diseases, and salivary gland damage. The company builds proprietary synthetic riboswitch controls alongside integrated in-house viral vector manufacturing. It is worth $795.53M on the market and sold $401.78M over the last year.

Market cap
$795.53M
P/E ratio
10.2×
Annual sales
$401.78M
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 15, 2026

MGTX’s flags, in plain English

Each flag is a number from MeiraGTx’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 15, 2026.

Stupid Cash

Can pay this year's bills 4.6 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Wide Gross Margin

Gross margin of 94.3% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Still Climbing

Sales up 39.2% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.

Thinly Traded

Thinly traded, about 834 shares a day, so prices can swing. Few shares change hands each day, so the price can jump on small orders and buying or selling can cost more.

2 more green flags open with the free trial. Try it free for 7 days.

Questions about MGTX

How big is MeiraGTx?

MeiraGTx’s market cap is $795.53M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $401.78M: what customers paid the company over the last year, before any costs.

What is MGTX’s P/E ratio?

MGTX’s P/E ratio is 10.2×. Investors pay about 10.2 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with MGTX?

The company operates without commercial product sales and reports ongoing operating losses from clinical trial costs. That is one risk on MeiraGTx’s card. Its first risk flag is Thinly Traded, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From MeiraGTx’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. MGTX’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card